Cancer Stem Cell News Volume 10.16 | Apr 28 2021


    2021-04-28 | CSCN 10.16

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.16 – 28 April, 2021

    iPSC Modeling of Stage-Specific Leukemogenesis Reveals BAALC as a Key Oncogene in Severe Congenital Neutropenia

    Researchers established a model of stepwise leukemogenesis in congenital neutropenia (CN)/acute myeloid leukemia using CRISPR-Cas9 gene editing of CN patient-derived iPSCs.
    [Cell Stem Cell]

    AbstractGraphical Abstract
    Microscopy images of pluripotent stem cells (PSCs) and PSC-derived cells for the #StemCellfie contest.
    PUBLICATIONSRanked by the impact factor of the journal

    Targeting the Metabolic Vulnerability of Acute Myeloid Leukemia Blasts with a Combination of Venetoclax and 8-Chloro-Adenosine

    Using acute myleoid leukemia cell lines (AML) and leukemia stem cell-enriched blast cells from pre-treatment AML patients, investigators evaluated the effects of 8-chloro-adenosine (8-Cl-Ado), venetoclax and the 8-Cl-Ado/VEN combination on fatty acid metabolism, glycolysis and oxidative phosphorylation using liquid scintillation counting, a Seahorse XF Analyzer and gene set enrichment analysis.
    [Journal of Hematology & Oncology]

    Full Article

    EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma

    Scientists established two sorafenib-resistant, patient-derived tumor xenografts that mimicked development of acquired resistance to sorafenib in hepatocellular carcinoma patients.
    [Cancer Research]


    Inhibition of Mitochondrial Translation Suppresses Glioblastoma Stem Cell Growth

    Researchers explored the therapeutic potential of targeting mitochondrial translation and report the results of high-content screening with putative blockers of mitochondrial ribosomes.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Glutamine Deficiency Promotes Stemness and Chemoresistance in Tumor Cells through DRP1-Induced Mitochondrial Fragmentation

    Investigators showed that glutamine is dispensable for the survival of ovarian and colon cancer cells while it is required for their proliferation.
    [Cellular and Molecular Life Sciences]


    NKX6-1 Mediates Cancer Stem-Like Properties and Regulates Sonic Hedgehog Signaling in Leiomyosarcoma

    NKX6-1 enhanced in vitro tumor cell aggressiveness via upregulation of cell proliferation and anchorage-independent growth and promoted in vivo tumor growth.
    [Journal of Biomedical Science]

    Full Article

    Monitoring Levels of Vimentin-Positive Circulating Cancer Stem Cells and Tumor Cells in Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

    The cell surface vimentin antibody was used for circulating tumor cells detection and CD133 antibody for circulating CSC detection.
    [Lung Cancer]


    Schisandrin B Inhibits Epithelial-Mesenchymal Transition and Stemness of Large-Cell Lung Cancer Cells and Tumorigenesis in Xenografts via Inhibiting the NF-κB and p38 MAPK Signaling Pathways

    Investigators established cancer stem‑like cells derived from large‑cell lung cancer cells, NCI‑H460 and H661, and revealed that Schisandrin B inhibited the viability of cancer stem‑like cells at concentrations of ≥40 µmol/l.
    [Oncology Reports]


    Nano-Realgar Suppresses Lung Cancer Stem Cell Growth by Repressing Metabolic Reprogramming

    Isolation and characterization of lung CSCs was performed by magnetic cell sorting and immunocytochemistry, respectively.

    The StemSpan™ T Cell Generation Kit is designed to promote differentiation of HSPCs into T cells in stroma- and serum-free culture conditions.

    A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy

    The authors report on various studies in this field which focus on transformative properties of CSCs and their influence on surrounding cells or targets through the release of cellular cargo in the form of extracellular vesicles.
    [Oncotargets and Therapy]

    Full Article

    D&D Pharmatech Announces Sponsored Research Agreement with Yale University to Optimize Novel Strategies for the Treatment of Brain Cancer and Other Diseases of the Central Nervous System

    D&D Pharmatech, Inc. announced it has entered into a sponsored research agreement with Yale University relating to optimization of two novel approaches that allow immune system cells and drug molecules to bypass the blood-brain barrier for the treatment of brain cancer and other disorders.
    [D&D Pharmatech, Inc. (Business Wire, Inc.))]

    Press Release

    Shorla Pharma Announces FDA Filing Acceptance and Priority Review for T-Cell Leukemia Treatment

    Shorla Pharma Limited announced that it has submitted, and the FDA has accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia.
    [Shorla Pharma Limited (BusinessWire, Inc.)]

    Press Release

    Oncolytic Viruses

    May 25, 2021

    > See All Events


    Head of Department – Gastrointestinal Cancer

    Indiana University School of Medicine – Indianapolis, Indiana, United States

    Postdoctoral Training Fellow – Pancreatic Cancer

    Francis Crick Institute – London, England, United Kingdom

    Project Associate – Prostate Cancer Clinical Trials Consortium

    Memorial Sloan Kettering – New York, New York, United States

    Director – Oncology, Diabetes

    Baylor Research Institute – Dallas, Texas, United States

    Postdoctoral Research Scientist Positions – Gastrointestinal Oncology

    Columbia University Medical Center – New York, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter